Myleran, Busilvex(busulfan)
Busulfan, Busulfex, Myleran (busulfan) is a small molecule pharmaceutical. Busulfan was first approved as Myleran on 1982-01-01. It is used to treat BCR-ABL positive chronic myelogenous leukemia, polycythemia vera, and primary myelofibrosis in the USA. It has been approved in Europe to treat hematopoietic stem cell transplantation.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Busulfan, Busulfex, Myleran (discontinued: Busulfan)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Busulfan
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BUSULFEX | Otsuka | N-020954 RX | 1999-02-04 | 1 products, RLD, RS |
| MYLERAN | Waylis Therapeutics | N-009386 RX | 1982-01-01 | 1 products, RLD, RS |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| polycythemia vera | — | D011087 | D45 |
| primary myelofibrosis | — | D055728 | D47.4 |
| bcr-abl positive chronic myelogenous leukemia | EFO_0000340 | D015464 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
759 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 50 | 193 | 42 | 5 | 38 | 284 |
| Myelodysplastic syndromes | D009190 | — | D46 | 37 | 141 | 23 | 2 | 21 | 199 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 35 | 123 | 34 | 1 | 29 | 195 |
| Lymphoma | D008223 | — | C85.9 | 31 | 112 | 8 | 2 | 18 | 152 |
| Myeloid leukemia | D007951 | — | C92 | 17 | 79 | 24 | 1 | 19 | 121 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 19 | 69 | 7 | 2 | 19 | 105 |
| Multiple myeloma | D009101 | — | C90.0 | 21 | 73 | 4 | 1 | 14 | 103 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 10 | 62 | 4 | 1 | 12 | 79 |
| Hematologic neoplasms | D019337 | — | — | 17 | 49 | 3 | 1 | 12 | 70 |
| Plasma cell neoplasms | D054219 | — | — | 13 | 51 | 4 | 1 | 7 | 68 |
Show 15 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Preleukemia | D011289 | — | — | 16 | 76 | 9 | — | 10 | 99 |
| Syndrome | D013577 | — | — | 13 | 65 | 11 | — | 12 | 88 |
| Neoplasms | D009369 | — | C80 | 20 | 41 | 3 | — | 15 | 71 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 12 | 51 | 6 | — | 9 | 68 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 5 | 33 | 2 | — | 4 | 39 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 13 | 24 | 6 | — | 4 | 36 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 6 | 22 | 3 | — | 4 | 32 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 6 | 20 | 3 | — | 5 | 31 |
| Plasmacytoma | D010954 | — | C90.3 | 2 | 23 | 1 | — | 4 | 29 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 6 | 15 | 6 | — | 6 | 29 |
Show 71 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 13 | 58 | — | — | 8 | 72 |
| Hodgkin disease | D006689 | — | C81 | 13 | 37 | — | — | 9 | 52 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 9 | 37 | — | — | 8 | 50 |
| Primary myelofibrosis | D055728 | — | D47.4 | 7 | 23 | — | — | 6 | 34 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 4 | 15 | — | — | 5 | 23 |
| Follicular lymphoma | D008224 | — | C82 | 4 | 14 | — | — | 5 | 22 |
| Myeloid leukemia accelerated phase | D015465 | — | — | 4 | 17 | — | — | 3 | 22 |
| Burkitt lymphoma | D002051 | — | C83.7 | 3 | 14 | — | — | 6 | 22 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 4 | 12 | — | — | 5 | 20 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | 4 | 13 | — | — | 4 | 19 |
Show 121 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinoblastoma | D012175 | — | — | 4 | — | — | — | 2 | 6 |
| Neuroectodermal tumors | D017599 | — | — | 2 | — | — | — | 3 | 5 |
| Primitive neuroectodermal tumors | D018242 | — | — | 1 | — | — | — | 3 | 4 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | — | — | — | 1 | 4 |
| Melanoma | D008545 | — | — | 3 | — | — | — | 1 | 4 |
| Rhabdomyosarcoma | D012208 | — | — | 3 | — | — | — | 1 | 4 |
| Wilms tumor | D009396 | EFO_0000212 | — | 3 | — | — | — | 1 | 4 |
| Testicular neoplasms | D013736 | — | C62 | 1 | — | — | — | 2 | 3 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 3 | — | — | — | — | 3 |
| Rhabdoid tumor | D018335 | — | — | 2 | — | — | — | 1 | 3 |
Show 29 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 hyper-igm immunodeficiency syndrome | D053307 | — | — | — | — | — | — | 2 | 2 |
| Hyper-igm immunodeficiency syndrome | D053306 | Orphanet_101088 | D80.5 | — | — | — | — | 2 | 2 |
| Mucositis | D052016 | EFO_1001898 | — | — | — | — | — | 2 | 2 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | — | — | — | 1 | 1 |
| Retinal neoplasms | D019572 | — | C69.2 | — | — | — | — | 1 | 1 |
| Phenylketonurias | D010661 | — | E70.0 | — | — | — | — | 1 | 1 |
| Agammaglobulinemia | D000361 | — | D80.1 | — | — | — | — | 1 | 1 |
| Leukocyte-adhesion deficiency syndrome | D018370 | EFO_1001359 | — | — | — | — | — | 1 | 1 |
| Hereditary congenital and neonatal diseases and abnormalities | D009358 | — | — | — | — | — | — | 1 | 1 |
| Monoclonal gammopathy of undetermined significance | D008998 | EFO_1000836 | D47.2 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Busulfan |
| INN | busulfan |
| Description | Busulfan is a methanesulfonate ester that is butane-1,4-diol in which the hydrogens of the hydroxy groups are replaced by methanesulfonyl groups. An alkylating antineoplastic agent, it is used for the treatment of chronic myeloid leukemia (although it has been largely replaced by newer drugs). It is also used as an insect sterilant. It has a role as an insect sterilant, an antineoplastic agent, a teratogenic agent, a carcinogenic agent and an alkylating agent. It is functionally related to a butane-1,4-diol. |
| Classification | Small molecule |
| Drug class | antineoplastics, alkylating agents (methane sulfonate derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)OCCCCOS(C)(=O)=O |
Identifiers
| PDB | — |
| CAS-ID | 55-98-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL820 |
| ChEBI ID | 28901 |
| PubChem CID | 2478 |
| DrugBank | DB01008 |
| UNII ID | G1LN9045DK (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,725 documents
View more details
Safety
Black-box Warning
Black-box warning for: Busulfan, Busulfex, Myleran
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,614 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use